- Conditions
- Von Willebrands Disease
- Interventions
- Not listed
- Lead sponsor
- Jonathan Roberts
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Peoria, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–45
of 45
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Von Willebrand Diseases
- Interventions
- Wilate
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Hemophilia A, Von Willebrand Disease
- Interventions
- Neumega (Oprelvekin, Interleukin 11, IL-11)
- Biological
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Von Willebrand Disease
- Interventions
- von Willebrand factor (Recombinant), Antihemophilic Factor (Recombinant)
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 8
- States / cities
- Loveland, Colorado • Gainesville, Florida • Jacksonville, Florida + 5 more
- Conditions
- Von Willebrand Disease, Type 3
- Interventions
- Von Willebrand Factor Concentrates, Von Willebrand Factor Concentrates and Factor VIII Concentrates, Factor VIII Concentrates, Recombinant Activated Factor VII, Activated Prothrombin Complex Concentrate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Sacramento, California • Minneapolis, Minnesota • St Louis, Missouri
- Conditions
- Von Willebrand Disease
- Interventions
- Vonicog alfa, Antihemophilic Factor (Recombinant)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 16
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more
- Conditions
- Von Willebrand Disease
- Interventions
- Not listed
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Von Willebrand Disease
- Interventions
- Neumega (Oprelvekin, Interleukin 11, IL-11)
- Drug
- Lead sponsor
- Margaret Ragni
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Von Willebrand Disease (VWD)
- Interventions
- rVWF, rFVIII
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Aurora, Colorado • Gainesville, Florida + 5 more
- Conditions
- VWD - Von Willebrand's Disease
- Interventions
- Not listed
- Lead sponsor
- VWD Connect Foundation
- Other
- Eligibility
- Not listed
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Wellington, Florida
- Conditions
- Platelet Dysfunction, Von Willebrand Diseases, Healthy, Congenital Platelets Abnormality
- Interventions
- T-TAS 01 PL Chip, PFA-100 Col/Epi and Col/ADP
- Diagnostic Test
- Lead sponsor
- Hikari Dx, Inc.
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- San Francisco, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
- Conditions
- Von Willebrand Disease
- Interventions
- Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII), Marketed plasma-derived VWF/FVIII concentrate
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 10
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 7 more
- Conditions
- Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
- Interventions
- ALN-6400
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 16 Years to 45 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Orange, California • San Diego, California • San Francisco, California + 3 more
- Conditions
- Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3, Von Willebrand Disease, Type 2A, Von Willebrand Disease, Type 2M, Von Willebrand Disease, Type 2N
- Interventions
- Clinical outcomes of patients with VWD, Type 1, Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3
- Other
- Lead sponsor
- Hemab ApS
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
- Conditions
- Von Willebrand Disease, Type 3
- Interventions
- Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Sacramento, California • Gainesville, Florida • Lexington, Kentucky + 3 more
- Conditions
- Von Willebrand Diseases, Postpartum Hemorrhage
- Interventions
- Recombinant Von Willebrand factor, Tranexamic Acid Injection [Cyklokapron]
- Drug
- Lead sponsor
- Nicoletta C Machin
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Von Willebrand Disease, Type 1, Heavy Menstrual Bleeding
- Interventions
- Volta System
- Device
- Lead sponsor
- Five Liters, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Von Willebrand Disease
- Interventions
- Patients using Wilate as standard of care
- Other
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 4
- States / cities
- Torrance, California • Miami, Florida • Salt Lake City, Utah + 1 more
- Conditions
- Von Willebrand Diseases
- Interventions
- Not listed
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- Not listed
- Enrollment
- 108 participants
- Timeline
- 2019 – 2026
- U.S. locations
- 22
- States / cities
- Orange, California • Aurora, Colorado • Farmington, Connecticut + 19 more
- Conditions
- Von Willebrand's Disease (VWD)
- Interventions
- efanesoctocog alfa (BIVV001)
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Pittsburgh, Pennsylvania
- Conditions
- Von Willebrand Disease (VWD)
- Interventions
- Vonicog Alfa, ADVATE
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Orlando, Florida • Peoria, Illinois + 9 more